CN114127064B - 4H-吡咯并[3,2-c]吡啶-4-酮化合物 - Google Patents

4H-吡咯并[3,2-c]吡啶-4-酮化合物 Download PDF

Info

Publication number
CN114127064B
CN114127064B CN202080031189.4A CN202080031189A CN114127064B CN 114127064 B CN114127064 B CN 114127064B CN 202080031189 A CN202080031189 A CN 202080031189A CN 114127064 B CN114127064 B CN 114127064B
Authority
CN
China
Prior art keywords
pyridin
pyrrolo
tetrahydro
methoxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080031189.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114127064A (zh
Inventor
S.西格尔
F.西格尔
V.舒尔茨
M.伯格
K.格雷厄姆
D.苏尔兹勒
U.伯默
D.科尔
J.施罗德
U.蒙宁
M.尼休斯
M.迈耶森
H.格罗伊利希
B.卡普兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Dana Farber Cancer Institute Inc
Broad Institute
Original Assignee
Bayer AG
Dana Farber Cancer Institute Inc
Broad Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70456765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114127064(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Dana Farber Cancer Institute Inc, Broad Institute filed Critical Bayer AG
Priority to CN202311716707.8A priority Critical patent/CN117986251A/zh
Priority to CN202311714944.0A priority patent/CN117946100A/zh
Publication of CN114127064A publication Critical patent/CN114127064A/zh
Application granted granted Critical
Publication of CN114127064B publication Critical patent/CN114127064B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202080031189.4A 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物 Active CN114127064B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202311716707.8A CN117986251A (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物
CN202311714944.0A CN117946100A (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962838051P 2019-04-24 2019-04-24
US62/838,051 2019-04-24
US201962940036P 2019-11-25 2019-11-25
US62/940,036 2019-11-25
PCT/EP2020/061176 WO2020216781A1 (en) 2019-04-24 2020-04-22 4h-pyrrolo[3,2-c]pyridin-4-one compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202311716707.8A Division CN117986251A (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物
CN202311714944.0A Division CN117946100A (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物

Publications (2)

Publication Number Publication Date
CN114127064A CN114127064A (zh) 2022-03-01
CN114127064B true CN114127064B (zh) 2023-12-26

Family

ID=70456765

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080031189.4A Active CN114127064B (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物
CN202311716707.8A Pending CN117986251A (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物
CN202311714944.0A Pending CN117946100A (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202311716707.8A Pending CN117986251A (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物
CN202311714944.0A Pending CN117946100A (zh) 2019-04-24 2020-04-22 4H-吡咯并[3,2-c]吡啶-4-酮化合物

Country Status (32)

Country Link
US (2) US12679836B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959211B1 (cg-RX-API-DMAC7.html)
JP (1) JP7641913B2 (cg-RX-API-DMAC7.html)
KR (1) KR102915019B1 (cg-RX-API-DMAC7.html)
CN (3) CN114127064B (cg-RX-API-DMAC7.html)
AU (1) AU2020262221B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019998B1 (cg-RX-API-DMAC7.html)
CA (1) CA3137218A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002770A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014022A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210530A (cg-RX-API-DMAC7.html)
DK (1) DK3959211T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2021000216A (cg-RX-API-DMAC7.html)
EC (1) ECSP21077614A (cg-RX-API-DMAC7.html)
ES (1) ES3068321T3 (cg-RX-API-DMAC7.html)
FI (1) FI3959211T3 (cg-RX-API-DMAC7.html)
GE (2) GEAP202415804A (cg-RX-API-DMAC7.html)
HR (1) HRP20260409T1 (cg-RX-API-DMAC7.html)
IL (1) IL287390B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210285A1 (cg-RX-API-DMAC7.html)
LT (1) LT3959211T (cg-RX-API-DMAC7.html)
MA (1) MA55751B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021012987A (cg-RX-API-DMAC7.html)
PE (1) PE20220254A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552693A1 (cg-RX-API-DMAC7.html)
PL (1) PL3959211T3 (cg-RX-API-DMAC7.html)
PT (1) PT3959211T (cg-RX-API-DMAC7.html)
RS (1) RS68081B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111304UA (cg-RX-API-DMAC7.html)
TW (1) TWI849114B (cg-RX-API-DMAC7.html)
UA (1) UA130453C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020216781A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
MX2023003362A (es) * 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
EP4244225B1 (en) * 2020-11-11 2026-06-03 Bayer Aktiengesellschaft N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl}oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
JP2024517808A (ja) * 2021-05-06 2024-04-23 セルジーン コーポレーション N-((r)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((s)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミドによる治療方法
IL315739A (en) * 2022-03-24 2024-11-01 Scorpion Therapeutics Inc Methods of synthesizing egfr inhibitors
WO2023205595A2 (en) * 2022-04-20 2023-10-26 Celyn Therapeutics, Inc Egfr inhibitors in cancer treatment
CA3270236A1 (en) 2024-08-28 2026-04-10 Bayer Aktiengesellschaft Stable solid pharmaceutical dosage form comprising crystalline form of her2/mutegfr inhibitor and process for its preparation
CA3270230A1 (en) 2024-08-28 2026-04-10 Bayer Aktiengesellschaft Crystalline forms of her2/mutegfr inhibitors and process for their preparation
CN119264091B (zh) * 2024-09-04 2025-05-27 康龙化成手性医药技术(宁波)有限公司 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010145998A1 (en) * 2009-06-15 2010-12-23 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
CN106715415A (zh) * 2014-06-17 2017-05-24 拜耳制药股份公司 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮
CN107406417A (zh) * 2015-01-28 2017-11-28 拜耳制药股份公司 4H‑吡咯并[3,2‑c]吡啶‑4‑酮衍生物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
DE102006033140A1 (de) 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
JP2008291023A (ja) 2007-04-27 2008-12-04 Sumitomo Chemical Co Ltd アミド化合物とその用途
EP2188292B1 (en) 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
CN101367801B (zh) 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2976336A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
ES2722431T3 (es) 2014-12-08 2019-08-12 Bayer Pharma AG Novedosos compuestos de aril-cianoguanidina
WO2016100166A1 (en) 2014-12-15 2016-06-23 Bristol-Myers Squibb Company SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS
WO2016185333A1 (en) 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010145998A1 (en) * 2009-06-15 2010-12-23 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
CN106715415A (zh) * 2014-06-17 2017-05-24 拜耳制药股份公司 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮
CN107406417A (zh) * 2015-01-28 2017-11-28 拜耳制药股份公司 4H‑吡咯并[3,2‑c]吡啶‑4‑酮衍生物

Also Published As

Publication number Publication date
US20250136599A1 (en) 2025-05-01
CL2021002770A1 (es) 2022-05-27
RS68081B1 (sr) 2026-05-29
DK3959211T3 (da) 2026-04-27
AU2020262221B2 (en) 2025-11-20
CN117946100A (zh) 2024-04-30
JP2022532850A (ja) 2022-07-20
ES3068321T3 (en) 2026-05-29
CN114127064A (zh) 2022-03-01
MA55751B1 (fr) 2026-04-30
CO2021014022A2 (es) 2022-03-29
WO2020216781A1 (en) 2020-10-29
IL287390B1 (en) 2025-07-01
BR112021019998A2 (cg-RX-API-DMAC7.html) 2021-12-07
UA130453C2 (uk) 2026-02-25
MX2021012987A (es) 2022-04-01
ECSP21077614A (es) 2021-11-30
CA3137218A1 (en) 2020-10-29
TWI849114B (zh) 2024-07-21
BR112021019998B1 (pt) 2024-01-16
HRP20260409T1 (hr) 2026-06-05
PE20220254A1 (es) 2022-02-16
EP3959211B1 (en) 2026-02-18
KR20220004103A (ko) 2022-01-11
JOP20210285A1 (ar) 2023-01-30
PT3959211T (pt) 2026-04-23
MA55751A (fr) 2022-03-02
LT3959211T (lt) 2026-06-10
FI3959211T3 (fi) 2026-04-01
CR20210530A (es) 2021-12-23
PH12021552693A1 (en) 2022-03-21
TW202106683A (zh) 2021-02-16
GEAP202415804A (en) 2024-02-12
DOP2021000216A (es) 2022-05-15
IL287390A (en) 2021-12-01
CN117986251A (zh) 2024-05-07
AU2020262221A1 (en) 2021-11-18
GEP20247648B (en) 2024-07-25
KR102915019B1 (ko) 2026-01-21
PL3959211T3 (pl) 2026-07-27
US12679836B2 (en) 2026-07-14
US20220298157A1 (en) 2022-09-22
JP7641913B2 (ja) 2025-03-07
IL287390B2 (en) 2025-11-01
SG11202111304UA (en) 2021-11-29
EP3959211A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
CN117986251A (zh) 4H-吡咯并[3,2-c]吡啶-4-酮化合物
US11339157B1 (en) 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
JP6704398B2 (ja) 4H−ピロロ[3,2−c]ピリジン−4−オン誘導体
US12403135B2 (en) 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN107207507B (zh) 1,3-噻唑-2-基取代的苯甲酰胺
CN106715415A (zh) 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮
US20240307362A1 (en) 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
US20230064983A1 (en) 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
CA3201333A1 (en) N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
HK40069903A (en) 4h-pyrrolo[3,2-c]pyridin-4-one compounds
HK40110212A (en) 4h-pyrrolo[3,2-c]pyridin-4-one compounds
HK40110192A (en) 4h-pyrrolo[3,2-c]pyridin-4-one compounds
HK40069903B (en) 4h-pyrrolo[3,2-c]pyridin-4-one compounds
EA046642B1 (ru) 4Н-ПИРРОЛО[3,2-с]ПИРИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069903

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant